Evidence map›Paper›PMID 29733972›Full record

ArticleInternational journal of pharmaceutics2018

Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy.

Dale Farkas, Michael Hindle, P Worth Longest

Open access · greenAbstract read
In one paragraph

Article in International journal of pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Journal of aerosol medicine and pulmonary drug delivery · 2022
    Article
  14. Article
  15. Article
  16. Administration of dry powders during respiratory supports.Annals of translational medicine · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dale FarkasDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States. Electronic address: farkasdr@vcu.edu.
Michael HindleDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States. Electronic address: mhindle@vcu.edu.
P Worth LongestDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, United States; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, United States. Electronic address: pwlongest@vcu.edu.
Virginia Commonwealth University · US

Funding

High Efficiency Delivery of Surfactant Aerosols to Infants without IntubationR01HL139673 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HINDLE, MICHAEL, LONGEST, P. WORTH · 2018 to 2021
$2.8M
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic FibrosisR01HD087339 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI HINDLE, MICHAEL, LONGEST, P. WORTH · 2017 to 2021
$2.5M
NHLBI NIH HHS R01 HL139673NICHD NIH HHS R01 HD087339
6 · The paper itself

Abstract

Inline dry powder inhalers (DPIs) offer a potentially effective option to deliver high dose inhaled medications simultaneously with mechanical ventilation. The objective of this study was to develop an inline DPI that is actuated using a low volume of air (LV-DPI) to efficiently deliver pharmaceutical aerosols during low flow nasal cannula (LFNC) therapy. A characteristic feature of the new inline LV-DPIs was the use of hollow capillary tubes that both pierced the capsule and provided a pathway for inlet air and exiting aerosol. Aerosolization characteristics, LFNC depositional losses and emitted dose (ED) were determined using 10 mg powder masses of a small-particle excipient enhanced growth (EEG) formulation. While increasing the number of inlet capillaries from one to three did not improve performance, retracting the inlet and outlet capillaries did improve ED by over 30%. It was theorized that high quality performance requires both high turbulent energy to deaggregate the powder and high wall shear stresses to minimize capsule retention. Best case performance included a device ED of approximately 85% (of loaded dose) and device emitted mass median aerodynamic diameter of 1.77 µm. Maximum ED through the LFNC system and small diameter (4 mm) nasal cannula was approximately 65% of the loaded dose. Potential applications of this device include the delivery of high dose inhaled medications such as surfactants, antibiotics, mucolytics, and anti-inflammatories.

Indexed as

CannulaInhalation SpacersAdministration, InhalationAerosolsAlbuterolDry Powder InhalersEquipment DesignAerosolsAlbuterolActive DPIHigh dose inhaled medicationsHigh efficiency DPIInline DPILow flow oxygen nasal cannulaNose-to-lung aerosol deliveryPediatric aerosol delivery

Identifiers

PMID29733972
PMCPMC7253153
OpenAlexW2801549405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.